Description

In most cases broad-spectrum monotherapy is sufficient for empiric therapy of febrile neutropenia. The Infectious Diseases Society of America (IDSA) has listed indications for adding antibiotic coverage against Gram-positive organisms to the empiric regimen.


 

Patient selection: febrile neutropenia

 

Indications for addition of antibiotic coverage for Gram-positive bacteria:

(1) severe sepsis (hemodynamic instability, etc)

(2) pneumonia seen on imaging studies

(3) positive blood culture for a Gram-positive bacteria prior to speciation

(4) clinical evidence for a serious intravascular catheter-associated infection (cellulitis around the catheter, pus, chills or rigors with infusion, etc)

(5) soft tissue infection of any site

(6) skin infection of any site

(7) colonization with a antibiotic-resistant Gram-positive bacteria

(8) severe mucositis (if fluoroquinolone used for prophylaxis and if ceftazidime used as empiric therapy)

 

where:

• Antibiotic resistant Gram-positive bacteria may include: methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), vancomycin-resistant enterococcus (VRE).

 


To read more or access our algorithms and calculators, please log in or register.